Back to Agenda
Session 3 Track B - Labeling and Advertising and Promotion: Implementation of Health Canada’s revised Guidance for Industry: Review of Drug Brand Names
Session Chair(s)
Marc Poitras, PhD, MBA
Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada, Canada
![Margaret Zimmermann](/_Images/member/Generic_Image_Missing-Profile.jpg)
Margaret Zimmermann
Manager, Patient Safety Section, Marketed Health Products Directorate
Health Canada , Canada
On June 13, 2015, Health Canada’s Guidance for Industry: Review of Drug Brand Names became effective. This session will walk through the revised guidance document providing information on what constitutes a brand name, brand name changes requiring an assessment, and the information to be provided to Health Canada in demonstrating the acceptability of a proposed brand name. Industry/Health Canada Perspective on the implementation of the Guidelines will be also be presented.
Speaker(s)
![Margaret Zimmerman](/_Images/member/Generic_Image_Missing-Profile.jpg)
Overview of the Revised Guidance
Margaret Zimmerman
Health Canada (MHPD), Canada
Manager, Policy & Partnership, Marketed Health Products Directorate
![Ana Nesic, MPharm](/_Images/member/Generic_Image_Missing-Profile.jpg)
Perspective from a Labeling Reviewer
Ana Nesic, MPharm
Health Canada, Canada
Senior Regulatory Policy & Risk Management Advisor
Implementation of the Revised Guidance
Tharany Ganesh
AstraZeneca Canada Inc., Canada
Head, Regulatory Affairs
Have an account?